ARTICLE | Company News
Hanmi, Innovent in bispecific antibody deal
March 30, 2017 10:39 PM UTC
Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940) and Innovent Biologics Inc. (Suzhou, China) partnered to co-develop and co-commercialize an immuno-oncology bispecific antibody. The compound is expected to begin clinical testing in 2019.
The candidate was developed using Hanmi's Pentambody bispecific engineering platform. Innovent will be responsible for its development and commercialization in China, and Hanmi elsewhere. The companies will share costs and profits...